1. France's Reimbursed Compassionate Access Pathway (Accès Compassionnel – AAC)
On behalf of eligible patients, we're pleased that France's health authority (ANSM) has authorized BOT+BAL for French patients through the AAC program—a positive step that validates its potential and provides fully reimbursed treatment in a hospital setting.
Treatment under AAC is governed by a national protocol that standardizes patient eligibility, treatment administration, data collection and follow-up under France’s ANSM. This means structured access with expert oversight and patient monitoring to ensure the best care is provided.
Who may qualify? Adult French patients with:
- MSS metastatic colorectal cancer without active liver metastases, following progression on standard therapies and not eligible for clinical trials,
- Platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, after being treated with approved treatment options, and
- Advanced or metastatic soft-tissue sarcomas, including multiple high-grade histologies, following failure of standard therapies
European Union and European Economic Area (EU/EEA) residents may be able to access treatment via cross-border care, often with home insurance coverage (check insurance for prior approval).
Easy steps for doctors:
Start by emailing Agenus Medical Affairs to learn more at: AAC@AgenusBio.com.
Patient details are not needed in your first message—we'll guide you from there.
